MAAT PHARMA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.94 EUR | +0.51% |
|
+0.51% | +13.75% |
| May. 08 | Mickey Mouse on Wall Street |  |
| Apr. 15 | MaaT Pharma: positive data in graft-versus-host disease | CF |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 131.9 | 79.15 | 80.99 | 109.8 | - | - |
| Enterprise Value (EV) 1 | 94.45 | 55.21 | 80.99 | 101.2 | 101.9 | 1,845 |
| P/E ratio | - | - | -4.11 x | -3.38 x | -3.31 x | -3.51 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 136 x | - | 36.4 x | 27.4 x | 25 x | 11.2 x |
| EV / Revenue | 97.2 x | - | 36.4 x | 25.3 x | 23.2 x | 188 x |
| EV / EBITDA | -11 x | - | -4.25 x | -3.67 x | -3.23 x | -74.4 x |
| EV / FCF | -11.6 x | -4.16 x | - | -2.86 x | -6.25 x | 280 x |
| FCF Yield | -8.65% | -24% | - | -35% | -16% | 0.36% |
| Price to Book | - | - | - | 18.8 x | -5.03 x | - |
| Nbr of stocks (in thousands) | 9,884 | 9,894 | 11,603 | 13,897 | - | - |
| Reference price 2 | 13.35 | 8.000 | 6.980 | 7.900 | 7.900 | 7.900 |
| Announcement Date | 4/14/22 | 3/31/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.136 | 0.972 | - | 2.228 | 4 | 4.4 | 9.8 |
| EBITDA 1 | - | -8.565 | - | -19.07 | -27.6 | -31.5 | -24.8 |
| EBIT 1 | - | - | - | -19.94 | -29.5 | -29.8 | -25.9 |
| Operating Margin | - | - | - | -895.11% | -737.5% | -677.27% | -264.29% |
| Earnings before Tax (EBT) 1 | - | - | - | -19.72 | -29 | -32.9 | -26.2 |
| Net income 1 | - | - | - | -19.72 | -29.6 | -29.9 | -26.2 |
| Net margin | - | - | - | -884.96% | -740% | -679.55% | -267.35% |
| EPS 2 | -25.70 | - | - | -1.700 | -2.335 | -2.385 | -2.250 |
| Free Cash Flow 1 | - | -8.167 | -13.27 | - | -35.43 | -16.3 | 6.6 |
| FCF margin | - | -840.23% | - | - | -885.83% | -370.45% | 67.35% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 10/4/21 | 4/14/22 | 3/31/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 1,736 |
| Net Cash position 1 | - | 37.5 | 23.9 | - | 8.6 | 7.9 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -69.98 x |
| Free Cash Flow 1 | - | -8.17 | -13.3 | - | -35.4 | -16.3 | 6.6 |
| ROE (net income / shareholders' equity) | - | - | - | - | -199% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | 0.4200 | -1.570 | - |
| Cash Flow per Share 2 | - | - | -1.270 | - | -2.060 | 0.3600 | 3.200 |
| Capex 1 | - | 0.24 | 0.66 | - | 1.93 | 1.77 | 1.45 |
| Capex / Sales | - | 24.49% | - | - | 48.33% | 40.15% | 14.8% |
| Announcement Date | 10/4/21 | 4/14/22 | 3/31/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.9
EUR
Average target price
14.6
EUR
Spread / Average Target
+84.81%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +13.75% | 119M | |
| +9.99% | 115B | |
| +12.01% | 106B | |
| -3.07% | 24.69B | |
| -0.73% | 21.97B | |
| -4.78% | 19.27B | |
| -6.90% | 17.56B | |
| -39.36% | 17.32B | |
| +5.82% | 14.03B | |
| +33.05% | 12.13B |
- Stock Market
- Equities
- MAAT Stock
- Financials MaaT Pharma
